Nektar Therapeutics (NKTR)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Howard W. Robin
|
CEO, President & Director | 2.33M | -- | 1953 |
|
Dr. Jonathan Zalevsky Ph.D.
|
Senior VP and Chief Research & Development Officer | 1.19M | -- | 1975 |
|
Ms. Linda M. Rubinstein M.A.
|
CFO and Principal Financial & Accounting Officer | -- | -- | 1967 |
|
Mr. Jason Barnard
|
Chief Accounting Officer | -- | -- | -- |
|
Ms. Elizabeth Zhang
|
VP of Legal, Corporate Counsel & Secretary | -- | -- | -- |
|
Mr. Spilios Asimakopoulos
|
Vice President of Commercial Strategy & Marketing | -- | -- | -- |
|
Mr. Robert Bacci
|
Chief People Officer and Head of Quality & Facilities | -- | -- | -- |
|
Ms. Jennifer Ruddock
|
Chief Business Officer | -- | -- | -- |
|
Dr. Mary Tagliaferri L.Ac., M.D.
|
Chief Medical Officer | -- | -- | 1966 |
|
Dr. Ken Franke Ph.D.
|
Senior Vice President of Biologics Process Development & Manufacturing | -- | -- | -- |
Nektar Therapeutics
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 63
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Corporate Governance
Upcoming Events
November 12, 2026 at 9:00 PM UTC
Nektar Therapeutics Earnings Date
